N-Acetylcysteine to Combat COVID-19: An Evidence Review

FDA Protects Covid-19 Vaccine Makers Seeks Withdrawal Of Competing Dietary Supplement
December 11, 2021
SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2
December 11, 2021

N-Acetylcysteine to Combat COVID-19: An Evidence Review

The novel coronavirus disease (COVID-19) is caused by a virus (SARS-Cov-2) and is known for inducing multisystem organ dysfunction associated with significant morbidity and mortality. Current therapeutic strategies for COVID-19 have failed to effectively reduce mortality rate, especially for elderly patients.

A newly developed vaccine against SARS-Cov-2 has been reported to induce the production of neutralizing antibodies in young
volunteers. However, the vaccine has shown limited benefit in the elderly, suggesting an agedependent immune response.

As a result, exploring new applications of existing medications could potentially provide valuable treatments for COVID-19. N-acetylcysteine (NAC) has been used in clinical practice to treat critically ill septic patients, and more recently for COVID-19 patients. NAC has antioxidant, anti-inflammatory and immune-modulating characteristics that may prove beneficial in the treatment and prevention of SARS-Cov-2. This review offers a thorough analysis of NAC and discusses its potential use for treatment of COVID-19.

Leave a Reply

Your email address will not be published.